medigraphic.com
SPANISH

Ginecología y Obstetricia de México

Federación Mexicana de Ginecología y Obstetricia, A.C.
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2016, Number 11

<< Back Next >>

Ginecol Obstet Mex 2016; 84 (11)

Heparin treatment “can it improve perinatal outcomes?”

Gómez-Alarcón A, González-Mirasol E, Arenas-Gómez B, López-Grande J, Gómez-García MT, González de Merlo G
Full text How to cite this article

Language: Spanish
References: 27
Page: 717-729
PDF size: 509.51 Kb.


Key words:

Antithrombotic treatment, Heparin, Pregnancy, Placenta complications.

ABSTRACT

Objetive: The main objective of this task consists on reviewing the existing literature in which the possible benefits of the antithrombotic therapy are studied in the prevention of complications caused by the placenta in order to acquire an acceptable clinical training and in order to suggest different areas of study related to this topic in a future.
Material and Method: In order to carry out this revision, a search of several studies published by Pubmed has been done. Clinical trials controlled in which it has been compared the possible benefit of the antithrombotic prenatal therapy opposite to the expectant conduct, in women with obstetric unfavorable precedents, with the aim to evaluate the prevention of complications caused by the placenta. In this revision, articles in which the effects of the heparin in techniques of assisted reproduction, abortions of repetition in the first trimester, antiphospholipid antibodies and thromboembolic venous diseases have not been included.
Results: After our research, 8 articles have been chosen with a total sample of 1178 women. Our revision shows a significant statistically reduction in the recurrence of hypertensive states of pregnancy (EHE), serious pre-eclampsia and minor for the gestational age (PEG) in those women who receive treatment with heparin during the pregnancy oppose to others who did not receive.
Conclusion: In spite of the fact that there seems to exist a decrease of recurrence of complications caused by the placenta such as EHE and PEG with the use of heparin, it is important to explain that in every clinical test included in our review, both the obstetric precedents, and the intervention, as well as the evaluated results are far between them for what the interpretation of the results must be done warily.


REFERENCES

  1. Kujovich JL. Thrombophilia and pregnancy complications. American Journal of Obstetrics and Gynecology. 2004; 191: 414-424

  2. ACOG Committee on Practice Bulletins. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Obstetrics and Gynecology. 2002; 77: 67-75

  3. Servicio de Medicina Maternofetal, Instituto Clínico de Ginecología, Obstetricia y Neonatología, Hospital Clínico de Barcelona. Hipertensión y gestación. Disponible en: https://medicinafetalbarcelona.org/clinica/images/protocolos/ patologia_materna_obstetrica/hipertensi%F3n%20 y%20gestaci%F3n.pdf. Actualizado en 2013

  4. Huppertz, B. Placental pathology in pregnancy complications. Thrombosis Research. 2011; 127, S96-S99

  5. Elizalde-Valdés VM, Calderón-Maldonado AE, García Rillo-A, Díaz Flores M. Abruptio placentae: morbimortalidad y resultados perinatales. Medicina e Investigación 2015;3(2):109-115

  6. Luckas M. Fetal growth restriction in Obstetrics and Gynecology. An evidence-based text for MRCOG. Luesley DM, Baker PN (eds). Arnold (Publ). London 2004; p. 245-52

  7. Lausman A, Kingdom J, Gagnon R, Basso M, Bos H, Crane J, Davies G, Delisle MF, Hudon L, Menticoglou S, Mundle W, Ouellet A, Pressey T, Pylypjuk C, Roggensack A, Sanderson F. Intrauterine growth restriction: sreeening, diagnosis, and management. Journal of Obstetrics and Gynaecology Canada. 2013; 35, 741-757

  8. Christiansen DM, Elklit A, Olff M. Parents bereaved by infant death: PTSD symptoms up to 18 years after the loss. General Hospital Psychiatry.2013; 35, 605-611

  9. Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, Walker LD, Greaves M, Brenkel I, Regan L, Greer IA. Thrombophilia in pregnancy: a systematic review. British Journal of Haemology. 2006; 132, 1271-196

  10. Rodger MA, Betancourt MT, Clark P, Lindqvist PG, Dizon- Townson D, Said J, Seligsohn U, Carrier M, Salomon O, Greer IA. The associatrion of factor V leiden and prothrombin gene mutation and placetna-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies. PloS Medicine. 2010; 7, e1000292

  11. Van Rijn BB, Hoeks LB, Bots ML, Franx A, Bruinse HW. Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia. American Journal of Obstetrics and Gynecology. 2006;195(3):723-728

  12. Rodger MA, Walker MC, Smith GN, Wells PS, Ramsay T, Langlois NJ, Carson N, Carrier M, Rennicks WR, Shachkina S, Wen SW. Is thrombophilia associated with placentamediated pregnancy complications? A prospective cohort study. Journal of Thrombosis and Haemostasis, 2014. 12, 469-478

  13. Florez J. Armijo JA, Mediavilla A. Farmacología de la hemostasia, la coagulación y la fibrinolisis. Farmacología humana. 5th ed. Elsevier; 2008. p. 899-903

  14. D´Ippolito S, Ortiz AS, Veglia M, Tersigni C, Di SN. Low molecular weight heparin in obstetric care: a review of the literature. Reproductive Sciences. 2011, 18, 602-613

  15. Greer IA, Brenner B, Gris JC. Antithrombotic treatment for pregnancy complications: which path for the journey to precision medicine? British Journal of Haematology. 2014. 165, 585-599.

  16. Kingdom JC, Drewlo S. Is heparin a placental anticoagulant in high-risk pregnancies. Blood. 2011. 118, 4780-4788

  17. Urrútia G, Bonfill X. Declaración Prisma: Una propuesta para mejorar la publicación de revisiones sistemáticas y metaanálisis. Medicina Clínica. 2010. 135(11), 507-511. http://www.elsevier.es/es-revista-medicina-clinica-2-articulo- declaracion prisma-una-propuesta-mejorar-S0025 775310001454?redirectNew=true

  18. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2008. Disponible en www.cochranehandbook. org

  19. Mello G, Parretti E, Fatini C, Riviello C, Gensini F, Marchionni M, Scarselli GF, Gensini GF, Abbate R. Low molecular weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensinconverting enzyme DD women. Hypertension. 2005. 45, 86-91

  20. Rey E, Garneau P, David M, Gauthier R, Leduc L, Michon N, Mortin F, Demers C, Kahn SR, Magee LA, Rodger M. Dalteparin for the prevention of recurrence of placental mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. Journal of Thrombosis and Haemostasis. 2009. 7, 58-64

  21. Gris JC, Chauleur C, Faillie JL, Baer G, Mares P, Fabbro-Peray P, Quere I, Lefrant JY, Haddad B, Dauzat M. Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. The pilot randomised controlled NOH-AP trial. Thombosis and Haemostasis. 2010. 104, 771-779

  22. Gris JC, Chauleur, C, Molinari N, Mares P, Fabbro-Peray P, Quere I, Lefrant JY, Haddad B, Dauzat M. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial. Thrombosis and Haemostasis. 2011. 106, 1053-1061

  23. Martinelli I, Ruggenenti P, Cetin I, Pardi G, Perna A, Vergani P, Acaia B, Facchinetti F, La Sala GB, Bozzo M, Rampello S, Marozio L, Diadei O, Gherardi G, Carminati S, Remuzzi G, Mannucci PM. Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood. 2012. 119, 3269-3275

  24. Rodger MA, Hague WM, Kingdom J, Kahn SR, Karovitch A, Sermer M, Clement AM, Coat S, Chan WS, Said F, Rey E, Robinson S, Khurana R, Demers C, Kovacs MJ, Solymoss S, Hinshaw K, Dwyer J, Smith G, McDonald S, Newstead- Angel J, McLeod A, Khandelwal M, Silver RM, Le Gal G, Greer IA, Keely E, Rosene-Montella K, Walker M, Wells PS; TIPPS Investigators. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with trombophilia (TIPPS): a multinational open-label randomised trial. The Lancet. 2014. 384(9955): 1673-1683

  25. de Vries JI, van Pampus MG, Hague WM, Bezemer PD, Joosten JH; FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Thrombosis and Haemostasis. 2012. 10(1): 64-72

  26. Kim M, Hayashi RH, Gambone JC. Obstetric Hemorrhage and Puerperal Sepsis. Abruptio Placentae. Essencial of Obstetrics and Gynecology. 5th ed. Philadelphia: Saunders- Elsevier; 2010. p. 130-131

  27. Hernández JM, Puente JM. Muerte fetal anteparto sin causa. Tratado de Ginecología, Obstericia y Medicina de la Reproducción. Cabero L (ed). Madrid: Ed. Panamericana. 2003. p 959-966.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Ginecol Obstet Mex. 2016;84